Adtran’s Oscilloquartz optical cesium clock outperforms in tests at leading European metrology institute
5.9.2023 15:00:00 EEST | Business Wire | Press release
Adtran today announced that one of the world’s leading metrology institutes has conducted a three-month-long evaluation of its OSA 3300-HP high-performance optical cesium atomic clock. Based in Central Europe, the national laboratory tested Adtran’s industry-first solution to establish its suitability for scientific measurement and calibration applications that require precise synchronization. The OSA 3300-HP succeeded in delivering the strict timing accuracy and long-term stability needed for metrology use cases with results far exceeding product specifications. The findings underline the value of Adtran’s Oscilloquartz optical cesium technology for a broad spectrum of industries, from astronomical research to defense operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905097567/en/
Adtran’s OSA 3300-HP has set new benchmarks for timing accuracy and long-term stability. (Photo: Business Wire)
“We’re pleased to see this validation for our OSA 3300-HP. As the market’s first commercial high-performance optical cesium atomic clock, it offers levels of performance that far exceed best-in-class magnetic cesium devices. Its unique capabilities have the potential to enhance the work of scientists and engineers in a diverse range of metrology, science, research, time scale and ground station fields, including space exploration,” said Gil Biran, GM of Oscilloquartz, Adtran. “Now that it’s achieved these successful results in some of the industry’s most thorough tests, science and research institutions across the world will be able to harness our device to bring new levels of accuracy to their work.”
Adtran’s OSA 3300-HP represents a major achievement in network synchronization. Building on Oscilloquartz’s 74-year history and the expertise of its team, the device provides a precise and ultra-stable frequency source for the most demanding and critical applications. It enables highly accurate synchronization over an extended 10-year lifetime thanks to its advanced optical cesium technology, which pumps atoms to the desired energy states more efficiently than legacy magnetic-based solutions. The OSA 3300-HP’s robust and compact design makes it suitable for multiple applications, even in ground space-constrained environments. It’s also fully compliant with the latest RoHS standards and strict EU demands.
“Assessments by this leading scientific evaluation center are recognized as among the most stringent evaluations in the world of metrology. By meeting and surpassing these rigorous standards, our OSA 3300-HP has proven its value for metrology, time-keeping institutes and scientific research. It will be the foundation for future innovation in sectors from satellite navigation to nanoscale technology,” commented Jörg Urban, AVP of EMEA business development at Oscilloquartz, Adtran. “Our optical pumping timing solutions have set a new benchmark for precision and availability. As well as having a transformative impact on metrology advancement, our technology provides the vital resilience required for PNT assurance in critical infrastructure. What’s more, it empowers communication service providers to harness robust and accurate GNSS backup to deliver valuable timing offerings with differentiated service level agreements.”
Further details including official results from the OSA 3300-HP evaluation are now available on request.
A brief summary of the findings can also be found in these slides.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and Twitter.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905097567/en/
Contact information
For media
Gareth Spence
+44 1904 699 358
public-relations@adva.com
For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
